Literature DB >> 33314632

A one-step assay for sorted CD3+ cell purity and chimerism after hematopoietic stem cell transplantation.

Judith Desoutter1,2, Cédric Usureau1,2, Valentine Jacob1,2, Delphine Lebon2,3, Alexis Caulier2,3, Cécilia Da Costa2, Amandine Charbonnier3, Magalie Joris3, Jean-Pierre Marolleau2,3, Nicolas Guillaume1,2.   

Abstract

A hematopoietic chimerism assay is the laboratory test for monitoring engraftment and quantifying the proportions of donor and recipient cells after hematopoietic stem cell transplantation recipients. Flow cytometry is the reference method for determining the purity of CD3+ cells on the chimerism of selected CD3+ cells. In the present study, we developed a single-step procedure that combines the CD3+ purity assay (using the PCR-based Non-T Genomic Detection Kit from Accumol, Calgary, Canada) and the qPCR chimerism monitoring assay (the QTRACE qPCR assay from Jeta Molecular, Utrecht, the Netherlands). First, for the CD3+ purity assay, we used a PCR-friendly protocol by changing the composition of the ready-to-use reaction tubes (buffer and taq polymerase) and obtained a satisfactory calibration plot (R2 = 0.8924) with a DNA reference scale of 2 ng/μl. Next, 29 samples (before and after CD3 positive selection) were analyzed, the mean cell purity was, respectively, 19.6% ± 6.45 and 98.9% ± 1.07 in the flow cytometry assay; 26.8% ± 7.63 and 98.5% ± 1.79 in the PCR-based non-T genomic detection assay. Our results showed that the CD3+ purity assay using a qPCR kit is a robust alternative to the flow cytometry assay and is associated with time savings when combined with a qPCR chimerism assay.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Keywords:  T-cell selection; accumol; chimerism; hematopoietic stem cell transplantation; purity assay

Year:  2020        PMID: 33314632     DOI: 10.1111/tan.14168

Source DB:  PubMed          Journal:  HLA        ISSN: 2059-2302            Impact factor:   4.513


  1 in total

1.  Utility of assessing CD3+ cell chimerism within the first months after allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia.

Authors:  Mehdi Bendjelloul; Cédric Usureau; Pascaline Etancelin; Zuzana Saidak; Delphine Lebon; Loïc Garçon; Jean-Pierre Marolleau; Judith Desoutter; Nicolas Guillaume
Journal:  HLA       Date:  2022-01-30       Impact factor: 8.762

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.